Related Experiment Video

Updated: May 23, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth

Dong Joon Kim1, Yan Li, Kanamata Reddy

  • 1The Hormel Institute, University of Minnesota, Minneapolis, Minnesota 55912, USA.

Cancer Research
|April 24, 2012
PubMed

Insights

Researchers identified HI-TOPK-032, a novel inhibitor of T-LAK cell-originated protein kinase (TOPK), which is crucial in cancer. This specific inhibitor shows potential for developing new colorectal cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • T-LAK cell-originated protein kinase (TOPK/PBK) is a serine-threonine kinase implicated in tumor development, cancer progression, apoptosis, and inflammation.
  • TOPK represents a promising therapeutic target for cancer treatment, yet no specific inhibitors have been reported.

Purpose of the Study:

  • To identify and characterize a novel inhibitor of TOPK.
  • To evaluate the efficacy of the identified inhibitor in preclinical models of colorectal cancer.

Main Methods:

  • Screening of 36 drug candidates using in vitro kinase assays to identify TOPK inhibitors.
  • In vitro assessment of HI-TOPK-032's specificity against related kinases (ERK1, JNK1, p38).
  • Evaluation of HI-TOPK-032's effects on colon cancer cell proliferation, apoptosis, and tumor growth in vivo using a xenograft model.

Main Results:

  • HI-TOPK-032 was identified as a potent and specific inhibitor of TOPK kinase activity in vitro.
  • HI-TOPK-032 demonstrated significant inhibition of colon cancer cell growth and induction of apoptosis by modulating key signaling pathways (ERK-RSK, p53, caspase-7, PARP).
  • In vivo studies confirmed that HI-TOPK-032 suppressed tumor growth in a colorectal cancer xenograft model.

Conclusions:

  • HI-TOPK-032 is a novel, specific inhibitor of TOPK with demonstrated anti-cancer activity both in vitro and in vivo.
  • HI-TOPK-032 holds potential as a therapeutic agent for colorectal cancer and warrants further clinical development.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...